|Articles|August 1, 2003

August 2003
Volume 9
Issue 8

Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Author(s)K. Tom Xu, PhD, Michael Moloney, MD, MPH, Sidney Phillips, PharmD

Download PDF: Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Articles in this issue

about 23 years ago

Article

What Data Do California HMOs Use to Select Hospitals for Contracting?

about 23 years ago

Article

Patient-Provider Discussions About Conflicts of Interest in Managed Care: Physicians' Perceptions

about 23 years ago

Article

Combination Vaccines

about 23 years ago

Article

Risk Factors for Asthma Hospitalizations in a Managed Care Organization: Development of a Clinical Prediction Rule

about 23 years ago

Article

Analysis of Factors Associated With Increased Prescription Illegibility: Results From the National Ambulatory Medical Care Survey, 1990-1998

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Economics of Suboptimal Drug Use: Cost-Savings of Using JNC-Recommended Medications for Management of Uncomplicated Essential Hypertension

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care